Browse Studies About FAQ

Sign in Get started

Match. Apply. Get paid. The simplest way to participate in paid clinical research.

Product

Browse Studies How it Works Verification Arctuva Pro For Sponsors

Company

About Contact FAQ

Legal

Privacy Terms of Service Security Accessibility Transparency Report

© 2026 Arctuva, Inc. All rights reserved.

Compensation is for time and inconvenience, not income.

Browse Studies — Arctuva | Arctuva

Browse studies

Find your next paid study

1 recruiting study matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.

Mutant IDH1 Inhibitor Olutasidenib

~$150 – $3,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT06445959